Analyses Of Healthcare Resource Utilization (Hcru) In Checkmate 141, A Phase 3 Study Of Nivolumab Versus Investigator'S Choice (Ic) In Patients With Recurrent Or Metastatic (R/M) Platinum-Refractory Squamous Cell Carcinoma Of The Head And Neck (Scchn)